Loading...
XSHG
688298
, Last price  
Name

Zhejiang Orient Gene Biotech Co Ltd

Chart & performance

D1W1MN
XSHG:688298 chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-0.51%
Rev. 5Y
-21.92%
Div Yld LY
—
Div Yld TTM
—
Revenues
947m
+14.43%
182,255,119224,237,368285,892,847367,376,8203,265,355,63710,169,167,7148,767,938,105820,157,331827,916,211947,379,903
Net income
-574m
L+8.43%
35,627,02232,705,73965,369,55782,105,1881,677,358,7434,920,188,1512,067,714,329-397,583,593-529,022,759-573,598,190
CFO
-194m
L-44.33%
11,808,62533,544,72744,326,05954,212,0731,790,306,6825,203,853,6452,995,924,491-1,602,077,753-348,326,855-193,899,048
Dividend
Jun 26, 20232 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunological diagnosis; quantum-beads flowcytometry; instrument; dry biochemical strips; raw materials; FISH probes; animal health; biochemistry; molecular diagnosis; and quantum-beads multiplex. Zhejiang Orient Gene Biotech Co., Ltd was founded in 2005 and is based in Huzhou, China.
IPO date
Feb 05, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT